HemoCath


HemoCath is dedicated to improving healthcare for critically ill patients and people living with heart failure by pioneering innovations at the intersection of Digital Health and MedTech. They develop the Swan-HemoCath™ Critical Care AI Platform, which integrates pulmonary artery catheters with AI-guided diagnosis, treatment, and monitoring to enhance patient outcomes, reduce hospital stays, and lower healthcare costs. Inspired by Dr. Jeremy Swan's legacy, the company aims to advance critical care with next-generation pulmonary artery catheters and continuous monitoring solutions.

Industries

health-diagnostics
medical-device

Nr. of Employees

small (1-50)


Products

Minimally invasive pulmonary artery (PA) catheter (prototype)

A small-diameter (4F) pulmonary artery catheter engineered for insertion via a brachial vein to measure pulmonary artery pressure and central venous pressure continuously; designed for portability and MRI compatibility. Prototype status; not approved for clinical use.


Services

Cloud-based AIoT hemodynamic monitoring platform (B2B SaaS)

A cloud platform that ingests continuous catheter-derived hemodynamic data, applies AI analytics for diagnosis and treatment support, and provides remote monitoring and data aggregation for clinical teams and researchers.

Expertise Areas

  • Hemodynamic monitoring
  • Critical care monitoring
  • Heart failure management
  • Digital health and AIoT platform development
  • Show More (3)

Key Technologies

  • Pulmonary artery catheterization
  • Hemodynamic measurement (PAP, CVP)
  • Continuous physiological signal acquisition
  • Cloud-based AI analytics
  • Show More (5)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.